Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Jenna who wrote (9052)	5/5/1998 3:56:00 PM
From: AlienTech	Read Replies (1) \| Respond to of 120523

I'HAVE GONE BLIND AND CAI'NT GIET IT UP! Sheesh, All this cause of a lil blindness.. Who woulda guessed.. From the Wall Street Journal Interactive ... "Vivus Shares Gain 10% As Doctors Warn Against Viagra NEW YORK (Dow Jones)--A warning from eye doctors that Pfizer Inc.'s (PFE) Viagra may prove dangerous to some patients with eye problems is giving a boost to Vivus Inc. (VVUS), which has its own answer to male impotence. The warning energized Vivus's Nasdaq shares, which were recently up 15/16, or 10.1%, to 10 3/16 on volume of 2.5 million shares. When Pfizer's Viagra blasted onto the impotence treatment scene last month it quickly generated upward of 40,000 prescriptions a day. In contrast, Vivus' MUSE suppository treatment more quietly has been used to help men suffering from impotence. But Monday the American Academy of Opthamology, the largest organization of eye doctors, said high doses of Viagra can cause some eye problems, including retinal dysfunction, light sensitivity and bluish-tinged vision. The consortium urged patients with retina problems, including macular degeneration or retinitis pigmentosa, to use the lowest possible dosages of the drug. According to PaineWebber analyst Charles Olsziewski, Vivus stands to benefit from potential problems with Viagra as impotent men look elsewhere for help. "The product works very successfully," Olsziewski said, referring to Vivus' suppository. "And that is also true for patients who are not suited for the pill." A Vivus representative wasn't immediately available for comment. Pfizer shares were recently trading at 110, down 2 11/16, or 2.3%, on volume of 4.6 million shares. -Nancy Beiles; 201-938-5393"